NMRA241220P2500
- 0.10
- 0.000.00%
Neumora Therapeutics Newsroom
Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode
This Biotech's Stock Could Double If Its Treatment for Major Depressive Disorder Succeeds, Says Mizuho
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $30
Neumora Therapeutics, Inc.: Strategic Advancements and Unique Efficacy in MDD Trials Drive Buy Rating
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $23
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI) and Lexicon Pharmaceuticals (LXRX)
Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target
Neumora Therapeutics | 10-Q: Q3 2024 Earnings Report
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript Summary
Neumora Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
Neumora Therapeutics | 8-K: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | Neumora Therapeutics Inc Q3 Shr View $-0.39 -- LSEG IBES Data
Express News | Neumora Q3 EPS $-0.45
Express News | Neumora: Financial Position Now Expected to Support Operations Into Mid-2026
Neumora Therapeutics 3Q Loss $72.5M >NMRA
Neumora Therapeutics 3Q Loss/Shr 45c >NMRA
Press Release: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating
Mizuho Securities Remains a Buy on Neumora Therapeutics, Inc. (NMRA)